VIVUS Inc. (NASDAQ:VVUS) represented a move of -0.66 percent or $-0.01 per share and closed its previous day trading session at $0.47. 757498 Shares were traded in the last trading session with an Average Volume of 700.94 Million Shares. The stock currently has a Market Capitalization of 55.13 Million.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company’s lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.
The stock traded between $0.380 and $1.380 over 1-Year time period showing its price to sales ratio of 0.41. VIVUS Inc. (NASDAQ:VVUS) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-8.02 and 200-Day Simple Moving Average of $-46.35. Its Price to Free Cash Flow is 0 and Price to Book of 0.
Analyst’s recommended the stock as 3 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, VIVUS Inc. (NASDAQ:VVUS) reported its Actual EPS of $-0.06/share. The analysts offering Earnings Estimates for the company were believing that VIVUS Inc. could bring EPS of $-0.13/share. The difference between Actual EPS and Estimated EPS was 0.07 Percent. Thus showing an Earnings Surprise of 53.8 Percent.
Organovo Holdings, Inc. (NASDAQ:ONVO)
In the last trading session, Organovo Holdings, Inc. (NASDAQ:ONVO) added its value by 3.67% closing at the price of $1.13. The stock currently has market capitalization of 129.63 Million, with average volume of 1.37 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Organovo Holdings, Inc. (NASDAQ:ONVO) is showing beta of 2.25. This particular value of beta suggests that Organovo Holdings, Inc. (NASDAQ:ONVO) has historically moved 225% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Organovo Holdings, Inc. (NASDAQ:ONVO) is at $-0.36.
The stock currently has RSI of 30.55. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California.
Organovo Holdings, Inc. (NASDAQ:ONVO) topped its 52-week high price of $3.26 on 03/20/17 and 52-Week Low Price of $0.93 on 02/09/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 14.91% and monthly volatility of 7.53% respectively.